How well does Pegasys(Peginterferon alfa-2a) work?

PEGASYS (peginterferon alfa-2a) is primarily used to treat chronic hepatitis C (CHC) and chronic hepatitis B (CHB) by inducing an immune response that inhibits viral replication, reducing liver inflammation and fibrosis.

Therapeutic Effect of PEGASYS in Hepatitis C and B Treatment

PEGASYS acts as an immunomodulatory agent, enhancing the body’s innate immune response to fight chronic viral infections such as hepatitis C and B. In chronic hepatitis C (CHC), it is used in combination with other antiviral drugs to reduce viral load and improve liver function in patients with compensated liver disease. When used in chronic hepatitis B (CHB), it reduces viral replication and alleviates liver inflammation. The therapeutic effect is achieved through its action on the interferon receptors, modulating immune cells to enhance antiviral activity, thereby leading to reduced viral burden and improved clinical outcomes. PEGASYS is also indicated for pediatric use in both CHC and CHB, offering significant therapeutic benefit for young patients with compensated liver disease.